Voyager Therapeutics careers

We diligently select and optimize AAV vectors that are best suited for each program. We systematically develop and optimize delivery techniques that are best suited for a particular disease. Members of our team have co-discovered many of the known naturally occurring AAV capsids. We have efforts underway to genetically engineer capsids to yield vectors with desirable properties, such as enhanced tissue specificity and improved delivery of genes to the brain and spinal cord. Efforts are also underway to optimize novel AAV capsids that demonstrate enhanced blood-brain barrier penetration for the potential treatment of CNS diseases following systemic administration of the AAV gene therapy vector. We are also pursuing a surgical approach for direct injection into a targeted region of the brain, coupled with real-time MRI in the case of our Parkinson’s disease and Huntington’s disease programs, or injection into the cerebrospinal fluid for broader delivery to the cells within and surrounding the spinal cord for our ALS and Friedreich’s ataxia programs. For our vectorized antibody programs targeting tau and alpha-synuclein, we are pursuing an intravenous route of administration.